Tag - PSTI

Markets

Dawson James cuts Pluristem to neutral after Phase 3 miss

Dawson James downgraded Pluristem Therapeutics (NASDAQ:PSTI) to “neutral” from “buy” and removed its price target after a Phase 3 trial investigating muscle regeneration following hip surgery did not meet the primary...

July 14, 2022

Developments

Pluristem terminates Phase 3 critical limb ischemia trial

Pluristem Therapeutics (NASDAQ:PSTI) reported disappointing results from an interim analysis of its Phase 3 study evaluating PLX-PAD for the treatment of critical limb ischemia. Based on the interim analysis, the study...

December 9, 2020

Developments

FDA clears Pluristem IND for PLX-PAD in COVID-19-related ARDS

Pluristem Therapeutics (NASDAQ:PSTI) received FDA clearance for an IND application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with intramuscular injections of PLX-PAD. ...

May 8, 2020

Markets

HCW ups Pluristem PT to $15.50 from $3.50 post reverse split

H.C. Wainwright raised its price target for Pluristem Therapeutics (NASDAQ:PSTI) to $15.50 from $3.50, reflecting a 10-for-1 reverse stock split and promising early results from a Phase 1 study. The stock closed at $4...

September 17, 2019

Tag - PSTI

Dawson James cuts Pluristem to neutral after Phase 3 miss

Pluristem terminates Phase 3 critical limb ischemia trial

FDA clears Pluristem IND for PLX-PAD in COVID-19-related ARDS

HCW ups Pluristem PT to $15.50 from $3.50 post reverse split

General

More